Workflow
Pharmaceuticals
icon
搜索文档
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
Businesswire· 2025-10-01 14:00
PHILADELPHIA--(BUSINESS WIRE)-- #AdultVaccination--GSK plc (LSE/NYSE: GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends across 387 different metro areas* to get insights on adult immunization at the local level. Vaccine Track now also includes a full decade of data, providing a longer look at adult vaccination trends over time. Previously, the site focused on sta ...
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Forbes· 2025-10-01 13:55
WASHINGTON, DC - SEPTEMBER 30: Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump as Centers for Medicare & Medicaid Services Mehmet Oz looks on after Trump announced a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Photo by Win McNamee/Getty Images)Getty ImagesPfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and ...
Takeda Pharmaceutical to exit cell therapy research
Reuters· 2025-10-01 13:41
Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development. ...
PainReform Provides Business Update for the Six Months Ended June 30, 2025
Globenewswire· 2025-10-01 13:27
TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D following parti ...
Focus: Drugmakers pressured with Trump tariffs after price‑cut talks faltered
Reuters· 2025-10-01 13:11
U.S. President Donald Trump's threat to impose 100% tariffs on branded drugs ratcheted up pressure on pharmaceutical companies to agree price cuts and shift manufacturing after talks faltered earlier this year, industry lobbyists and executives said. ...
GoodRx expands tie-up with Kroger to offer branded drugs at discounted price
Reuters· 2025-10-01 13:10
GoodRx said on Wednesday it has partnered with Kroger's healthcare unit to expand its prescription savings services for branded drugs, including Novo Nordisk's popular weight-loss drug Wegovy. ...
CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
Prnewswire· 2025-10-01 13:05
Accessibility StatementSkip Navigation Injectable Ibuprofen Approved for Treating Pain & Fever Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: The company also has a ser ...
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
Globenewswire· 2025-10-01 13:00
Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhance ...
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
Globenewswire· 2025-10-01 13:00
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants”) from Oram ...
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
Prnewswire· 2025-10-01 12:47
Accessibility StatementSkip Navigation — First ex-U.S. Regulatory Filing for SOLSOEC— — Pharma 1 Targets 1H 2026 Launch in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis, leveraging its commercial infrastructure and expertise in women's health — SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company P ...